logo
Zambia: Mining in Toxic Lead Waste Poisons Children

Zambia: Mining in Toxic Lead Waste Poisons Children

Zawya05-03-2025
In the Zambian city of Kabwe, children suffer severe health effects due to lead poisoning because of extreme pollution from the toxic lead waste of a former mine.
Zambia's government is facilitating new hazardous lead and zinc mining and processing of the toxic waste, posing major additional health risks to children.
The Zambian government should suspend operations, revoke licenses of companies involved in the hazardous activities, and embark on a full clean-up of Kabwe's lead waste.
Zambia 's government is facilitating hazardous mining and processing of toxic lead waste in the city of Kabwe that poses major health risks to children, Human Rights Watch said in a report released today. These business activities add to the harm faced by Kabwe residents, who have been exposed to toxic lead for decades from a former lead and zinc mine.
The 67-page report, ' Poisonous Profit: Lead Waste Mining and Children's Right to a Healthy Environment in Kabwe, Zambia,' documents the Zambian government's issuance of mining and processing licenses for South African, Chinese, and local businesses and its failure to intervene against blatant violations of Zambian environmental and mining law by several mining and processing companies.
'The Zambian government should be protecting people from highly hazardous activities, not enabling them,' said Juliane Kippenberg, associate children's rights director at Human Rights Watch. 'Companies are profiting in Kabwe from mining, removing, and processing lead waste at the expense of children's health.'
Human Rights Watch interviewed miners and community members in Kabwe and carried out open-source research and geospatial analysis. Human Rights Watch wrote to the government and 16 companies requesting information and received responses from the Ministry of Green Economy and Environment, the South African company Jubilee Metals Group, and a local businessman.
Lead is a highly toxic metal and is particularly harmful to children. It can result in coma and death, as well as intellectual disability and ill-health. During pregnancy, it can result in miscarriage and other complications. Researchers estimate that over 95 percent of children living near the former mine in Kabwe have elevated blood lead levels, and about half of them urgently require medical treatment.
Businesses have conducted or facilitated hazardous mining and processing to extract zinc, lead, or other minerals in lead-contaminated waste around Kabwe's former mine area between 2022 and late 2024. Companies have removed significant amounts of waste from the mine and placed open piles across Kabwe, putting the health of residents further at risk.
'The waste piles across Kabwe are very concerning,' said an 18-year-old activist. 'Number one, because children tend to play around them or on top of them. Also, those mountains of waste are taken to other places in Kabwe – they are not sealed off from the public, and this makes those areas toxic, too.'
Small-scale and artisanal miners have mined lead, zinc, and other minerals on the concession of Jubilee Metals' subsidiary, Enviro Processing Limited (EPL), which has a mining license for much of the former Kabwe mine area. Miners said that security guards at the site had allowed them to enter, though Jubilee Metals denies this. Hazardous artisanal mining in lead waste has also taken place at a nearby area controlled by a local politician. Miners said that they sometimes sold mined material to the Chinese processing companies Datong Industries, Chengde Mining, and Superdeal Investments.
In mid-2023, businesses and individuals began to remove large amounts of waste from the EPL concession by truck and to transport it to other parts of Kabwe. Several waste piles were placed outside the premises of processing companies. Satellite imagery analysis revealed that by January 2024, nine waste piles were visible. Several sources said that Kabwe Kamukuba Small Scale Mining Cooperative Society, a local cooperative involved in removing the waste in 2023, was connected to ruling party leaders who may have financially benefitted. The waste removal, which Jubilee Metals described as trespassing and theft, continued through 2024.
Globally, zinc and lead are highly sought-after metals, including for the world's urgently needed fossil fuel phaseout and transition to renewable energy. The Zambian government has designated zinc and lead in Kabwe as 'critical minerals' needed for the global energy transition.
The Zambian government has not done enough to enforce mining, environmental, and labor regulations, Human Rights Watch said. Under Zambian law, the government has the authority to sanction companies because of an 'unsafe working environment' or 'uncontrollable pollution.' The government, to Human Rights Watch's knowledge, has not taken such steps against businesses involved in the hazardous mining, removing, and processing of lead waste in Kabwe. The Zambia Environmental Management Agency has not published these businesses' environmental impact assessments, nor has it used its authority to suspend operations where they violate environmental law.
Small-scale and artisanal miners eke out a living by digging for minerals in the waste piles. Several women miners told Human Rights Watch that they take their children to work because they need the income. One is a 32-year-old mother who took her son to work until he developed severe memory problems at age fifteen. She told Human Rights Watch: 'We are constantly living in fear because it is not a safe area … [but] it is the only way I can sustain my children.… I would love a different job.'
Kabwe's mine was opened during the British colonial period and closed in 1994, leaving an estimated 6.4 million tons of uncovered lead waste dumps. Since then, lead has contaminated residential areas, exposing up to 200,000 people. In 2020, lawyers filed a class action lawsuit in a South African court against the mining company Anglo American for its alleged role—contested by the company—in the Kabwe mine from 1925 to 1974, seeking compensation, a lead-screening system for affected children and women, and remediation of the area. The court dismissed the case, but claimants have said they will appeal the decision.
While the Zambian government has taken some measures to mitigate Kabwe's lead contamination through the World Bank-funded Zambia Mining and Environmental Remediation and Improvement Project, it has failed to clean up the source of contamination. The government has recognized the need for a broader cleanup but has seemingly done little to put words into action. President Hakainde Hichilema has twice—in March 2022 and April 2024 —announced the creation of a government committee to address the contamination, but no committee has been set up.
The Zambian government should suspend operations and revoke licenses of companies involved in the hazardous mining, removal, and processing of lead-bearing waste in Kabwe, Human Rights Watch said. It should conduct a comprehensive program to provide a remedy for the former lead mine and its waste in close consultation with affected communities, civil society, and experts. To fund this effort, the Zambian government should seek technical and financial support from donor agencies and companies responsible for the pollution.
'The Zambian government should prioritize children's health over mining profit,' Kippenberg said. 'Only comprehensive remediation of the mine waste can protect children and future generations in Kabwe from toxic lead.'
Distributed by APO Group on behalf of Human Rights Watch (HRW).
Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

Life Sciences on the Chinese Mainland – Vital signs: Diagnosing trends in the life sciences real estate market on the Chinese mainland
Life Sciences on the Chinese Mainland – Vital signs: Diagnosing trends in the life sciences real estate market on the Chinese mainland

Arabian Post

time01-08-2025

  • Arabian Post

Life Sciences on the Chinese Mainland – Vital signs: Diagnosing trends in the life sciences real estate market on the Chinese mainland

HONG KONG SAR – Media OutReach Newswire – 1 August 2025 –Cushman & Wakefield, a leading global real estate services firm, today released itsreport. It is based on in-depth interview surveys we conducted on professionals active in the life sciences sector on the Chinese mainland. The life sciences industry on the Chinese mainland is undergoing a transformative phase, driven by progressive policies, groundbreaking innovations, the emergence of influential life sciences companies, and strategic regional development. This report delves into the latest trends shaping the sector. Policy Landscape – National and Local Catalysts Reforms enacted in 2024-2025 have significantly accelerated sector development. Nationally, China relaxed restrictions on foreign investment in gene and cell therapy and allowed the establishment of wholly foreign-owned hospitals in key cities. Regulatory incentives – such as data protection and marketing exclusivity – have improved market access for innovative drugs. Locally, cities like Beijing, Shanghai, Shenzhen, Guangzhou, and Suzhou are rolling out targeted subsidies, fast-track approvals, and ecosystem-building programmes that directly benefit biotech development. ADVERTISEMENT Recent national policy initiatives on the Chinese mainland Types of policies Detail information Opening to Foreign Investment In 2024, China eased restrictions on foreign investments in stem cell research, gene therapy, and genetic diagnostics within Free Trade Zones (FTZs) like Beijing, Shanghai, Guangdong, and Hainan. Regulatory Incentives The State Council's Circular No. 53 introduced measures such as regulatory data protection and marketing exclusivity for select pharmaceutical products, including orphan and paediatric drugs. Wholly Foreign-Owned Hospitals China now permits the establishment of wholly foreign-owned hospitals in cities like Beijing, Shanghai, and Shenzhen, enhancing healthcare services and encouraging foreign investment. Source: Cushman & Wakefield Research Industry Innovation and Company Growth Chinese life sciences companies are moving beyond generic drug manufacturing toward innovative therapies. Firms like Akeso, BeiGene, Gracell, and Legend Biotech are now global players, leading in CAR-T, bispecific antibodies, and AI-assisted R&D. These companies are not only commercialising cutting-edge treatments but also attracting international investment and licensing agreements, reinforcing the Chinese mainland's global relevance in life sciences. Real Estate Development and Regional Hubs ADVERTISEMENT Innovation hubs such as Suzhou BioBAY, Zhangjiang Hi-Tech Park (Shanghai), and the Bioisland Innovation Centre (Guangdong) are central to regional clustering. These hubs offer end-to-end support, including shared labs, venture capital access, GMP-compliant facilities, and proximity to academic and clinical networks. The rise of second-tier innovation cities like Chengdu and Ningbo further expands growth corridors. The 'R&D + Manufacturing + Service' ecosystem Source: Cushman & Wakefield Research Landlord Perspectives – Evolving Real Estate Models Real estate developers and landlords are adapting to sector-specific requirements through asset-light models, flexible leasing, and high-specification lab and production space. Tier-1 cities face saturation, but central and western regions exhibit healthy demand. Developers are incorporating advanced sustainability and compliance features to meet growing regulatory and ESG expectations, particularly in GMP and cleanroom environments. Digitalisation, environmental policies, and differentiated tenant strategies are shaping performance. Operators now focus on integrated ecosystems with platforms that link tenants to R&D services, policy benefits, and technology partners. Occupier Perspectives – Growth, Innovation, and Challenges Life sciences occupiers are navigating regulatory reform, rising compliance demands, and intensified market competition. Many are localising production and R&D, leveraging regional subsidies, and investing in AI-powered innovation platforms. Occupiers seek flexibility, proximity to talent and infrastructure, and co-located R&D and manufacturing to support accelerated innovation and operational agility. In real estate, demand is strongest for GMP-certified labs, modular production facilities, and shared innovation platforms. Occupiers emphasise location advantages, sustainability certifications (e.g., LEED, WELL), and integration into clusters that enable faster time-to-market. Tony Su, Managing Director, National Head of Industrial & Logistics Property Services, China, said, 'Life sciences business parks on the Chinese mainland demonstrated clear regional differentiation, highlighting opportunities for strategic positioning. While Tier-1 cities saw more moderate performance due to broader macroeconomic factors and abundant supply, core cities in central and western regions recorded healthy occupancy rates, underpinned by strong industrial clustering and increasingly sophisticated ecosystems – contributing to steady growth in asset value.' Johnathan Wei, President, Project & Occupier Services, China, said, 'Several interviewed life sciences companies on the Chinese mainland achieved revenue growth supported by innovative products and favourable policy tailwinds. While overall growth remained modest for many, a select group reported strong performance, highlighting opportunities for differentiation'. Andrew Chan, Managing Director, Head of Valuation & Advisory Services, Greater China, said,' Looking ahead to 2025 and beyond, growth opportunities lie in AI-driven drug discovery, personalised medicine, advanced therapeutics (CGT, RNA), and green-certified facilities. Government policies continue to support innovation through fast-track approvals, rare disease funding, and subsidies aligned with dual-carbon and ESG goals'. Shaun Brodie, Head of Research Content, Greater China, 'Life sciences real estate is shifting from generic parks to specialised, digitally enabled campuses with high compliance and flexibility. Investment strategies increasingly emphasise long-term partnerships, collaborative operating models, and digital infrastructure. Both landlords and occupiers express cautious optimism, with strategic differentiation and regional targeting seen as keys to unlocking future value'. Please click here to download the full report. Hashtag: #Cushman&Wakefield The issuer is solely responsible for the content of this announcement. About Cushman & Wakefield Cushman & Wakefield (NYSE: CWK) is a leading global commercial real estate services firm for property owners and occupiers with approximately 52,000 employees in nearly 400 offices and 60 countries. In Greater China, a network of 23 offices serves local markets across the region. In 2024, the firm reported revenue of $9.4 billion across its core services of Valuation, Consulting, Project & Development Services, Capital Markets, Project & Occupier Services, Industrial & Logistics, Retail, and others. Built around the belief that Better never settles, the firm receives numerous industry and business accolades for its award-winning culture. For additional information, visit or follow us on LinkedIn (

Oriental Remedies Clinic Opens Fifth TCM Clinic in Punggol Coast Mall
Oriental Remedies Clinic Opens Fifth TCM Clinic in Punggol Coast Mall

Arabian Post

time31-07-2025

  • Arabian Post

Oriental Remedies Clinic Opens Fifth TCM Clinic in Punggol Coast Mall

Warm, personalised TCM care for the whole family at Oriental Remedies Clinic, delivered in a thoughtfully designed space. SINGAPORE – Media OutReach Newswire – 31 July 2025 – Oriental Remedies Clinic, a Traditional Chinese Medicine (TCM) clinic chain in Singapore, has announced the opening of its new clinic in Punggol. Located at Punggol Coast Mall, the chain's fifth branch aims to cultivate a sanctuary for holistic family wellness, prioritising a nurturing and stress-free environment that offers a child-friendly experience for all ages. New Clinic Opening for Families in Punggol Coast Mall The new TCM clinic is designed as a welcoming space where families can experience the TCM principle of Yang Sheng, the art of life cultivation. More than just a treatment centre, it encourages individuals and children to build lifelong habits that promote balance, vitality, and preventive care. Developed in collaboration with House on the Hill, a renowned Montessori preschool in Singapore, the clinic features a sensory-focused waiting area thoughtfully designed to engage children through their five senses, transforming passive waiting into active discovery. Children are invited to explore traditional Chinese herbs, textures, scents, and natural materials in a calm, tactile environment. This immersive setup encourages curiosity, independent participation, and self-directed play, reflecting our core belief in nurturing lifelong wellness from an early age. ADVERTISEMENT Every aspect of the clinic promotes emotional comfort and a restorative atmosphere. A natural colour palette of muted greys and warm earth tones, complemented by carefully curated toys suited to different developmental stages, helps children feel grounded and focused. This intentional design supports emotional regulation and encourages internal awareness, an essential foundation for the mind-body connection central to TCM healing practices. Enhancing Comfort with Child-Friendly Design The clinic features an open-concept layout, where the paediatric pods for consultations and treatments are designed as a natural extension of the children's play area, offering a seamless transition from exploration to treatment. This thoughtful continuity reduces anxiety by preserving a sense of familiarity and playfulness, helping consultations feel more conversational and less clinical. These pods are intentionally designed to encourage gentle interaction, open communication and engagement, helping children stay emotionally regulated and present. This approach keeps children engaged and interested in their bodies and feelings, fostering a sense of ownership in their wellness journey. The open-concept design facilitates parental supervision, allowing the clinic to foster guided independence in children. Through this approach, the clinic helps empower children to understand and make choices that support their well-being. This transparency is key to the collaborative, family-centred approach at Oriental Remedies Clinic. Expanding Core Services to Support Paediatric Care In addition to Oriental Remedies Clinic's comprehensive suite of treatments, including acupuncture, herbal medication, paediatric tuina, and tech-enhanced therapies such as Electro-Lymphatic Therapy (ELT), the new branch will introduce more child-focused therapies, such as paediatric moxibustion, herbal vaporiser therapy, and Cell Pro Therapy for children. These specialised additions reflect the clinic's dedication to delivering tailored, gentle, and effective care while actively encouraging children's participation in their health education from an early age. ADVERTISEMENT The Punggol outlet will also serve as an educational platform through intimate community workshops. Covering practical topics such as 'Understanding Big Emotions through TCM,' 'Supporting Your Child's Immune System Naturally,' and 'Healthy Foods for Your Body Constitution,' these workshops aim to reinforce the critical link between emotional resilience, physical health, and lifelong wellness. Integrating Tradition with Technology in Punggol's Digital District Located at Punggol Coast Mall within the Punggol Digital District (PDD), the clinic's opening aligns with Singapore's push for innovation in healthcare. Oriental Remedies Clinic is actively exploring ways TCM can evolve through advancements in artificial intelligence, data analytics, and smart diagnostics. Current initiatives include research into AI-assisted tongue and pulse diagnosis, and personalised treatment plans informed by data analytics. These advanced technologies aim to enhance the precision of care without compromising the personalised, hands-on essence of traditional TCM practice. In the long term, the clinic hopes to collaborate with research institutions and tech firms within PDD to further integrate cutting-edge innovations into TCM. This forward-looking approach supports Oriental Remedies Clinic's vision of becoming a modern, future-ready wellness provider—empowering practitioners with technology to deliver more precise, effective, and accessible care. Supporting Healthier SG Through Early Education The expansion into Punggol reflects Oriental Remedies Clinic's dedication to Singapore's Healthier SG initiative, which prioritises preventive care. Understanding that establishing strong health foundations begins in childhood, the new clinic aims to help introduce TCM principles and healthy lifestyle practices in an engaging manner. By creating child-friendly spaces that foster curiosity and proactive exploration of natural remedies, the clinic chain helps children and families build strong foundations for lifelong health. This approach cultivates balanced living from an early age, ultimately reducing the incidence of chronic illnesses later in life. Through empowering children to embrace healthy habits from a young age, the chain looks to actively contribute to a more resilient and healthier Singapore. Serving the Punggol Community Through Holistic Care According to Beatrice Liu, CEO and co-founder of Oriental Remedies Clinic, the decision to open a new branch in Punggol was driven by the area's growing population and its high concentration of young families.'Punggol represents a vibrant, forward-looking community, and we see an immense opportunity to partner with these families on their wellness journeys,' says Ms. Liu.'Our focus on life cultivation means we are not just addressing immediate health concerns, but guiding individuals and families holistically through every stage of life, with care that evolves alongside them.' The new clinic at Punggol Coast Mall is now open. First-time patients can enjoy a special launch offer for a limited time. For more information or to register, please use our form here. Hashtag: #OrientalRemedies The issuer is solely responsible for the content of this announcement. About Oriental Remedies Clinic Oriental Remedies Clinic is a leading healthcare provider in Singapore that combines Traditional Chinese Medicine (TCM) with modern technology. The clinic has expanded from a single-physician practice to a team of bilingual practitioners, many of whom are trained in both Biomedical Science and TCM, combining scientific knowledge with the wisdom of traditional medicine.

Shanghai Healthcare M&A Fund Takes Strategic Stake in MicroPort Scientific Corporation
Shanghai Healthcare M&A Fund Takes Strategic Stake in MicroPort Scientific Corporation

Arabian Post

time25-07-2025

  • Arabian Post

Shanghai Healthcare M&A Fund Takes Strategic Stake in MicroPort Scientific Corporation

HONG KONG SAR – Media OutReach Newswire – 25 July 2025 – MicroPort Scientific Corporation (Stock Code: 'MicroPort') announced that Shanghai Healthcare M&A Fund ('SHMAF'), a fund managed by SIIC Capital, a subsidiary of SIIC Group, has entered into a share purchase agreement to acquire 135,335,204 shares in MicroPort held by Otsuka Medical Devices Co., Ltd. Through this transaction, SHMAF will become a strategic shareholder in MicroPort, underscoring its role as a state-backed, professionally operated platform that is creating value and empowering, stabilizing, developing, and reshaping leading biopharmaceutical companies in China. As a homegrown Chinese innovator that has grown into a global leader in high-end medical devices, MicroPort serves as an anchor company for the industry. Its stable development is critical to both China's and the global high-end medical device supply chain. This investment reflects SHMAF's capital-driven approach to providing crucial support to domestic anchor companies, ensuring their stability and support growth of their core assets. SHMAF will support MicroPort's growth momentum and high-quality sustainable development with its expansive resources. Introducing a strategic shareholder to drive growth momentum. The transaction brings in a significant strategic shareholder for MicroPort. Leveraging its state-backed resources and industrial expertise, SHMAF will support MicroPort's development needs, core business expansion, and potential strategic mergers and acquisitions to create synergies that bolster the company's ongoing innovation and scale-up its operations. ADVERTISEMENT Optimizing resource allocation to unlock synergistic value. MicroPort has successfully incubated and nurtured multiple listed companies and specialized, highly influential small companies, in the process establishing a unique MicroPort ecosystem. SHMAF will leverage its capital and operational integration expertise to support MicroPort in refining its development strategy, optimizing resource allocation, and unlocking synergistic value—while fully respecting market dynamics and corporate autonomy—to further strengthen its ecosystem and competitive advantages. Enhancing ecosystem to enhance anchor company value. MicroPort's product portfolio spans across ten major verticals, including cardiovascular intervention, rhythm management, orthopaedics, neurovascular intervention, and surgical robotics, making it a core player in the high-end medical device industrial chain. SHMAF's support will not only drive MicroPort's growth, it will also accelerate its consolidation of upstream and downstream companies in Shanghai, attract highly-skilled talent, and facilitate breakthroughs in critical technologies and core components—ultimately enhancing the global competitiveness of China's high-end medical device industry. This transaction marks another significant step in SHMAF's commitment to serving biopharmaceutical anchor companies. Upholding its value investment principles, SHMAF will collaborate with MicroPort's shareholders and management team to leverage the strategic support and industrial synergies its state-backed platform offers. Together, they will reinforce MicroPort's position as China's innovation engine in high-end medical devices and contribute to the advancement of the biopharmaceutical industry. Hashtag: #SIICCapital #MicroPort #SHMAF The issuer is solely responsible for the content of this announcement. About MicroPort Scientific Corporation Founded in 1998 and headquartered in Shanghai's Zhangjiang, MicroPort Scientific Corporation is a leading domestic innovative high-end medical device group. It began by breaking the import monopoly in the cardiovascular stent field, and after 26 years of innovative development, its business has expanded to areas including rhythm management, orthopaedics, cardiovascular intervention, aortic and peripheral vascular intervention, neurovascular intervention, heart valves, surgical robots, and surgical medical devices. By the end of 2024, MicroPort operated in over 20,000 hospitals across 100 countries and regions worldwide, providing more than 600 solutions for patients covering over 200 diseases. MicroPort has incubated 6 A-share and Hong Kong-listed companies, owns 9 specialized and sophisticated SMEs, 4 technology giant enterprises, and 16 national high-tech enterprises, making it an outstanding representative of Shanghai's technological innovation and industrial transformation. About SIIC Capital As the active fund management platform under SIIC Group, since its establishment, SIIC Capital has been based in Shanghai, connected with Hong Kong, and oriented towards the world, actively exploring investment opportunities in strategic emerging industries such as biomedicine and green environmental protection. Through a multi-currency, full-stage fund matrix layout, it deeply serves national strategies and the construction of biomedicine highlands.

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into a world of global content with local flavor? Download Daily8 app today from your preferred app store and start exploring.
app-storeplay-store